⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18000819 | 0.76 | ACHE (0.38) | — | |
| SCHEMBL18010537 | 0.71 | — | — | |
| SCHEMBL4022892 | 0.66 | L3MBTL1 (0.62) | — | |
| SCHEMBL293082 | 0.64 | — | — | |
| SCHEMBL3224996 | 0.57 | NPC1 (0.33) | — | |
| SCHEMBL18010525 | 0.56 | — | — | |
| SCHEMBL18603296 | 0.55 | — | — | |
| SCHEMBL6971219 | 0.52 | — | — | |
| SCHEMBL9786440 | 0.52 | — | — | |
| SCHEMBL11623307 | 0.50 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546107-B1 | COX-2 INHIBITING PYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-7446117-B2 | Cox-2 inhibiting pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20070270428-A1 | Use of Cyclooxygenase-2 Inhibitors for the Treatment of Depressive Disorders | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
| US-20070142411-A1 | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20060040988-A1 | Cox-2 Inhibiting pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| CN-1681788-A | COX-2 inhibiting pyridine derivatives | GLAXO GROUP LTD (GB) | 2005-10-12 | — | — | CN | disclosed |